The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.
Sheptulina A.F.
National Medical Research Center for Therapy and Preventive Medicine;
Russian University of Medicine
Bryk D.D.
National Medical Research Center for Therapy and Preventive Medicine
Mamutova E.M.
National Medical Research Center for Therapy and Preventive Medicine
Yafarova A.A.
National Medical Research Center for Therapy and Preventive Medicine
Drapkina O.M.
National Medical Research Center for Therapy and Preventive Medicine;
Russian University of Medicine
Clinical consequences of sarcopenic obesity. Part 1. Non-alcoholic fatty liver disease, type 2 diabetes mellitus, chronic kidney disease
Journal: Russian Journal of Preventive Medicine. 2024;27(8): 114‑120
Views: 342
Downloaded: 3
To cite this article:
Sheptulina AF, Bryk DD, Mamutova EM, Yafarova AA, Drapkina OM. Clinical consequences of sarcopenic obesity. Part 1. Non-alcoholic fatty liver disease, type 2 diabetes mellitus, chronic kidney disease. Russian Journal of Preventive Medicine.
2024;27(8):114‑120. (In Russ.)
https://doi.org/10.17116/profmed202427081114
Sarcopenic obesity is a condition characterized by excessive fat tissue accumulation in the body accompanied by reduced skeletal muscle mass and muscle strength. The definition of this state remains the subject of discussion. For example, there is no consensus among scientists and clinicians on whether only patients with reduced absolute skeletal muscle mass must be attributed to the category of individuals with sarcopenic obesity, or patients with obesity and a reduced proportion of skeletal muscles in the body should also be included in this category. Despite disagreements, it is clear that sarcopenic obesity is a particular, distinct nosological entity. Its defining feature is that compared to sarcopenia and obesity as separate diseases sarcopenic obesity is characterized by a much higher risk of complications, in particular type 2 diabetes mellitus, non-alcoholic fatty liver disease, chronic kidney disease, as well as by a more unfavorable prognosis. In addition, the process of body mass decrease, which often leads to additional loss of skeletal muscle mass, can be associated with an increased risk of decompensation of comorbidities and adverse outcomes due to the initially lower skeletal muscle mass in the body. In this review, we will elaborate on the interrelation between sarcopenic obesity and some of the most common and significant diseases associated with metabolic disorders as well as describe the probable mechanisms underlying this interrelation.
Keywords:
Authors:
Sheptulina A.F.
National Medical Research Center for Therapy and Preventive Medicine;
Russian University of Medicine
Bryk D.D.
National Medical Research Center for Therapy and Preventive Medicine
Mamutova E.M.
National Medical Research Center for Therapy and Preventive Medicine
Yafarova A.A.
National Medical Research Center for Therapy and Preventive Medicine
Drapkina O.M.
National Medical Research Center for Therapy and Preventive Medicine;
Russian University of Medicine
Received:
05.04.2024
Accepted:
10.04.2024
List of references:
Close metadata
Email Confirmation
An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.
Email Confirmation
Log in to the site using your account in one of the services
We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.